Liberty Health Sciences Appoints Jennifer Timothee Oliveras, M.D., as Medical Director

Dr. Timothee joins Liberty's Florida leadership team as the Company rolls out its Cannabis Education Centers statewide

TORONTO, March 21, 2018 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS or US OTCBB: LHSIF) (the "Company" or "Liberty") is pleased to announce that Jennifer Timothee Oliveras, M.D.  will be joining the Company as Medical Director, overseeing Liberty's patient-focused approach to selling medical cannabis. Dr. Timothee brings considerable expertise and she shares the Company's commitment to educating the public on the medical benefits of cannabis.

"We are honored and delighted to welcome Dr. Timothee as Liberty's new Medical Director," said George Scorsis, Director and CEO of Liberty. "With her extensive education, experience and passion for the benefits of medical cannabis, she brings added depth and strength to our organization as we continue our statewide expansion of our patient-focused Cannabis Education Centers."

Dr. Timothee was born in San Juan, Puerto Rico and as a young adult moved to Florida to begin her medical education. She completed her bachelor's degree in Microbiology and Cell Science at the University of Florida, then returned to Puerto Rico where she attended Medical School and completed her residency in Emergency Medicine.  She then returned to Florida where she has been a practicing emergency physician since 2013. Dr. Timothee is also on track to complete her MBA from the University of South Florida this summer.

"I'm proud to join such a high caliber, conscientious team and I share their dedication to making safe, high-quality and effective pharmaceutical-grade medical cannabis available to those in need," said Dr. Timothee. "I also look forward to raising public awareness about the many benefits of medical cannabis, and to supporting the Company's unique patient-centered philosophy."   

About Liberty Health Sciences Inc.

Liberty Health Sciences Inc. is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal.  Liberty's stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities.  Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer.  Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.

For more information, please visit www.libertyhealthsciences.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Liberty Health Sciences Inc.

For Canadian media inquiries, please contact: Hilary Sloan, Edelman, 416-908-2134, [email protected]; For U.S. media inquiries, please contact: David Schull or Nic Johnson, Russo Partners, [phone], [email protected], [email protected]